Has your physician recommended a stem cell transplant after several initial rounds of CTD? Several studies have shown that stem cell transplantation after CTD increases efficacy and survival. Of course, your eligibility for a transplant depends on your age and overall health.

Here are two articles about CTD therapy:

Cyclophosphamide-Thalidomide-Dexamethasone Combination Is Promising As First Line Treatment For Myeloma Prior To Stem Cell Transplant

Cyclophosphamide, Low-Dose Thalidomide, And Dexamethasone Combination Is Safe And Effective For Multiple Myeloma Patients

Life expectancy depends on a number of things, such as the stage of your myeloma, the aggressiveness of your myeloma, whether you have certain chromosomal abnormalities, your age, etc.

Dr. Kenneth Anderson, a leading myeloma expert said recently, “The median survival, especially in younger patients, is seven to eight years. Maintenance is adding at least another several years to that. So a newly diagnosed patient today has a likely median survival of over ten years.”

Dr. Bijay Nair from the University of Arkansas for Medical Sciences said, “No, skipping one dose will not adversely affect your outcome on this treatment regimen.”

Which information do you mean? Do you mean the information at the link at the end of the article that has the text “abstract 8014″? If so, the link should work. We just tried it.

Let us know exactly what information you’re looking for, and we’ll make sure you get it.